首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   171篇
  完全免费   29篇
  神经病学   200篇
  2019年   2篇
  2018年   6篇
  2017年   4篇
  2016年   16篇
  2015年   12篇
  2014年   18篇
  2013年   15篇
  2012年   12篇
  2011年   20篇
  2010年   21篇
  2009年   21篇
  2008年   24篇
  2007年   18篇
  2006年   2篇
  2005年   3篇
  2004年   3篇
  2003年   3篇
排序方式: 共有200条查询结果,搜索用时 31 毫秒
1.
代谢综合征是脑卒中的危险因素   总被引:7,自引:0,他引:7  
目的初步探讨代谢综合征与初发脑卒中的关系。方法选择905例初发脑卒中患者和500例正常对照,计算各组代谢综合征的现患率。测定纤维蛋白(原)、C-反应蛋白等指标。结果初发卒中患者代谢综合征的现患率是对照组的3倍;伴代谢综合征的脑卒中患者中,缺血性卒中(80.75%)所占比例显著超过出血性卒中,CRP和FIB(均P〈0.05)均明显高于同组不伴MS的患者及对照组。结论代谢综合征是脑卒中的危险因素之一,其机制可能与凝血纤溶系统、炎症等方面有关。  相似文献
2.
精神分裂症患者伴发代谢综合征的患病率调查   总被引:6,自引:1,他引:5  
目的调查国内精神分裂症患者中代谢综合征的患病率及分析可能的相关影响因素。方法对住院的精神分裂症患者进行问卷调查和实验室测定,代谢综合征的诊断标准采用2004年中华医学会糖尿病分会代谢综合征标准。结果符合入组条件者共完成602例。精神分裂症患者中代谢综合征患病率为35.5%。与代谢综合征患病风险相关的危险因素包括年龄、性别、抗精神病药物种类及精神分裂症的病程(P〈0.05)。Logistic回归分析结果显示,女性精神分裂症患者罹患代谢综合征的相对危险度明显高于男性。年龄的相对危险度为12.27(95%CI2.238-32.557)。抗精神病药物种类与代谢综合征的患病风险有关(P=0.047〈0.05)。结论与普通人群相比,精神分裂症患者具有较高的代谢综合征发病风险,可能的危险因素包括女性、高龄、病程长及服用氯氮平药物等。  相似文献
3.
住院精神分裂症患者代谢综合征的患病率及相关因素   总被引:3,自引:0,他引:3  
目的 了解住院精神分裂症患者代谢综合征的患病率及其相关因素.方法 对上海市精神卫生中心分部住院的精神分裂症患者作调查,测定其代谢指标,采用世界糖尿病联盟(IDF)全球统一标准定义代谢综合征.结果 共入组483人,其中男性272人(56.3%),女性211人(43.7%),平均年龄(53±10)岁(19~82岁).住院精神分裂症患者代谢综合征的患病率为43.9%(213/483),女性的患病率(118/211,55.9%)高于男性的(94/272,36.4%)(χ2=22.0,P<0.05).患病率随年龄增加而增加.大于41岁的患者中女性的代谢综合征患病率均高于男性.Logistic回归发现代谢综合征与性别有关.结论 在精神分裂症患者尤其女性患者中存在较多的代谢综合征,疾病早期即应予以关注.  相似文献
4.
长期住院治疗的精神分裂症患者代谢综合征风险研究   总被引:3,自引:0,他引:3  
目的调查长期服用抗精神病药的精神分裂症患者在糖脂代谢相关变量的情况及相关风险的评估,以便为进一步研究抗精神病药与代谢综合征发生的因果关系提供初步的调查线索。方法以上海市精神卫生中心住院诊断为精神分裂症且持续服用治疗剂量抗精神病药至少6个月以上而以往无代谢障碍的患者为调查对象,在6个病房中进行筛选,符合条件共170人,调查包括人口学资料(身高,体重,腰围,用药时间,糖尿病家族史)、最近一月的血脂水平(HDL,TG)、空腹血糖和血压等情况。结果精神分裂症患者中男性较女性更易罹患代谢综合征(P<0.01);精神分裂症患者中的吸烟者较不吸烟者更易罹患代谢综合征(P<0.05);而药物之间的比较并无显著性差异(P>0.05)。结论经典和非典型抗精神病药可能会引起代谢综合征或加重其发生的风险。  相似文献
5.
To elucidate the relationship between metabolic syndrome (MetS) and cerebrovascular stenosis, we performed comparative studies of MetS and its components between ischemic stroke patients with intra- and extracranial atherostenosis. We evaluated 378 acute ischemic stroke patients who underwent brain magnetic resonance (MR) imaging and MR angiography. Stenosis was diagnosed in cases showing a degree of luminal narrowing of ≥ 50%. The stroke subtypes were categorized as large artery atherosclerosis (LAA), small artery occlusion (SAO), cardioembolism (CE), and stroke of undetermined etiology (SUE). MetS was defined using the criteria of the Adult Treatment Panel III. The mean carotid intimal medial thickness values showed increased tendency as the number of MetS components increased ( P  < 0.001). Regardless of stroke subtype, the MetS (+) group showed an increasing tendency toward stenosis (LAA, SAO, all P  < 0.001; CE, P  = 0.001; SUE, P  = 0.077). MetS was independently associated with intracranial atherosclerosis (odds ratio, 3.58; 95% CI, 2.28–5.63), which was prominent with more severe MetS components after adjustment for other risk factors ( P  < 0.001). Amongst the component conditions, elevated blood pressure, increased blood glucose/hyperglycemia, and abdominal obesity were dominantly associated with stenosis (all P  < 0.001). Modifications of the individual MetS components need to be considered for stroke prevention because of intracranial atherogenic progression.  相似文献
6.
目的 探讨急性缺血性脑血管病(AICD)患者颈动脉粥样硬化(CA)的特点以及代谢综合征(MS)对CA的影响.方法 应用彩色多普勒超声仪检查514例AICD患者及300例对照组的颈动脉,比较两组颈动脉内中膜厚度(IMT)、斑块指数、CA发生率及MS患病率.按是否有CA将AICD患者分成CA组及非CA组,分析两组MS的患病率以及MS和其单一组分危险因素与CA的相关性.结果 (1)AICD组MS患病率、IMT、斑块指数及CA发生率均明显高于对照组,比较差异有统计学意义(P<0.05).(2)CA组MS、高血压、三酰甘油(TG)增高、低密度脂蛋白胆固醇(LDL-C)增高及总胆同醇(TC)增高的发生率高于非CA组,比较差异有统计学意义(P<0.05).(3)调整年龄、性别、吸烟史和其他单一组分危险因素后,MS依然增加CA患病的危险,其OR值为2.43.95%CI为1.81~3.96.(4)伴糖尿病的MS患者CA的患病危险度(OR值为22.46)是不伴糖尿病的MS患者的5.6倍(OR值为3.98).结论 AICD患者MS及CA患病率高,MS是CA的独立危险因素,并和其各单一组分危险因素及糖尿病相互作用促进CA的发生.  相似文献
7.
目的旨在初步研究伴有代谢综合征(metabolic syndrome,MS)的首发缺血性卒中(first-ever ischemicstroke,FIS)患者在入院时基线水平的性别差异。方法对2008年8月-2009年11月在北京天坛医院神经内科住院的连续入组的FIS患者进行横断面调查。依据国际糖尿病联盟(the International DiabetesFederation,IDF)2005年对MS的定义对入选患者进行分组,对比男性、女性患者之间的差异。结果602例FIS患者中,男411例(668.5%)、女191例(占31.7%),伴MS患者共234例,其中男117例,占男性FIS患者的28.5%;女11例,占女性FIS患者的61.3%。男性伴MS患者吸烟、饮酒发生率明显高于伴MS的女性(74.5%VS14.5%,P〈0.001;66.7%VS4.5%,P〈0.001)。中心性肥胖、低高密度脂蛋白、高血压发生率在女性明显高于男性(79.1%VS34.8%,P〈0.001;62.8%VS58.9%,P〈0.001;97.4%VS89.1%,P=0.024)。女性伴Ms的患者同女性不伴Ms的患者比较,患大动脉粥样硬化性(large artery atherosclerosis,LAA)缺血性卒中的风险更高(67.4%VS48.4%,P=0.011)。男性伴MS的患者同男性不伴MS的患者比较,在此卒中亚型上未见显著差异(29.2%VS25.5%,P=0.490)。结论在FIS患者中,女性患者Ms的发生率远高于男性患者。在伴有MS的FIS患者当中,和女性相比,男性更常见的危险因素为吸烟、饮酒;而和男性相比,女性更常见的危险因素为中心性肥胖及低高密度脂蛋白、高血压。伴MS的女性FIS患者,更易感LAA性缺血性卒中,而在伴MS的男性患者中未见到明显卒中亚型的差别。  相似文献
8.
糖尿病及代谢综合征患者的卒中预防   总被引:2,自引:0,他引:2  
卒中的发病率、致残率及再发风险均较高,且临床过程不可逆,因此预防至关重要.本文简要回顾了关于糖尿病(diabetes mellitus,DM)及代谢综合征(metabolic syndrome,MetS)患者卒中预防的最新研究进展.  相似文献
9.
BACKGROUND: The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial. METHODS: The change in proportion of subjects with MS and individual criteria was compared between antipsychotic treatment groups, along with mean changes for individual criteria. Primary analyses examined subjects with fasting laboratory assessments at baseline and 3 months. Other analyses examined 3-month changes in MS status, waist circumference (WC), HDL cholesterol and blood pressure in all subjects, metabolic changes at the end of phase 1 participation (EOP), and repeated measures changes in HDL, blood pressure (BP) and WC over phase 1. RESULTS: At 3 months, there were no significant between-drug differences for the change in proportion of subjects meeting MS status or individual MS criteria in the smaller fasting cohort (n = 281) or for those meeting criteria for parameters not dependent on fasting status (BP, HDL, WC) among all subjects (n=660). Among all subjects whose MS status could be determined at 3 months (n=660), MS prevalence increased for olanzapine (from 34.8% to 43.9%), but decreased for ziprasidone (from 37.7% to 29.9%) (p=.001). Although effect sizes varied across subgroups, at 3 months olanzapine and quetiapine had the largest mean increase in waist circumference (0.7 in. for both) followed by risperidone (0.4 in.), compared to no change for ziprasidone (0.0 in.) and a decrease in waist circumference for perphenazine (-0.4 in.). Olanzapine also demonstrated significantly different changes in fasting triglycerides at 3 months (+21.5 mg/dl) compared to ziprasidone (-32.1 mg/dl). EOP exposure data was obtained, on average, nine months from baseline for all metabolic variables. Results from EOP and repeated measures analyses were consistent with those at 3 months for mean changes in WC and fasting triglycerides, but between group differences emerged for HDL and SBP. CONCLUSIONS: This large non-industry sponsored study confirms the differential metabolic effects between antipsychotics. Clinicians are advised to monitor all metabolic parameters, including WC, HDL and serum triglycerides, during antipsychotic treatment.  相似文献
10.
OBJECTIVES: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic abnormalities in disorders other than schizophrenia in which antipsychotic medication is part of routine treatment. METHODS: Sixty consecutive patients with bipolar disorder (BD) at our university psychiatric hospital and affiliate services were entered in an extensive prospective metabolic study including an oral glucose tolerance test. The prevalence of the metabolic syndrome was assessed based on the National Cholesterol Education Program Adult Treatment Protocol (ATP-III) criteria, the adapted ATP-III criteria using a fasting glucose threshold of 100 mg/dL, and the recently proposed criteria from the International Diabetes Federation (IDF). RESULTS: The analysis of 60 patients showed a prevalence of the metabolic syndrome of 16.7% (ATP-III), 18.3% (adapted ATP-III) and 30.0% (IDF), respectively. A total of 6.7% of the patients met criteria for diabetes and 23.3% for pre-diabetic abnormalities. CONCLUSIONS: The metabolic syndrome and glucose abnormalities are highly prevalent among patients with BD. They represent an important risk for cardiovascular and metabolic disorders. Assessment of the presence and monitoring of metabolic abnormalities and its associated risks should be part of the clinical management of patients with BD.  相似文献
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号